All In Biotech

Drug Trial Radar · NCT01757275

High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer

A Multi-center, Randomised, Double-blind, Parallel-group Phase III Study to Assess High Dose Esomeprazole Na i.v. Treatment (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour Administered for 72 Hours) for Prevention of Rebleeding

Last checked: Nov 21, 2026Latest source record: Mar 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 239 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

239

Actual

Start

Feb 2013

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic ulcer, with cimetidine i.v. in

Conditions

  • Bleeding Peptic Ulcer

Interventions

  • Esomeprazole NaDrug

    Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous

  • CimetidineDrug

    Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours

  • Esomeprazole MgDrug

    40 mg tablet once daily for 27 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Clinically Significant Rebleeding Within 72 HoursTime frame: 72 hours

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chongqing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Ha'er Bing, China

  • Research Site

    Hangzhou, China

  • Research Site

    Jinan, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Shanghai, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.